Ezetimibe Placebo

DRUG4 trials

Sponsors

Organon and Co, Sanofi, NewAmsterdam Pharma

Conditions

ASCVDCoronary DiseaseDiabetes Mellitus, Type 2DyslipidemiasFamilial HypercholesterolemiaHigh CholesterolHypercholesterolemia

Phase 1

Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects

CompletedNCT01723735

SanofiHypercholesterolemia

Start: 2012-11-30End: 2013-07-31Updated: 2016-09-28

Phase 2

Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

CompletedNCT05266586

NewAmsterdam PharmaDyslipidemias, High Cholesterol, Hypercholesterolemia

Start: 2022-03-09End: 2022-09-08Updated: 2024-07-03

Phase 3

Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)

CompletedNCT00423488

Organon and CoCoronary Disease, Diabetes Mellitus, Type 2, Hypercholesterolemia

Start: 2005-07-12End: 2007-02-16Updated: 2022-02-09

Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

CompletedNCT06005597

NewAmsterdam PharmaASCVD, Dyslipidemias, Familial Hypercholesterolemia +2

Start: 2024-03-01End: 2024-10-16Updated: 2025-10-08

Related Papers

Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.

2025-05-0716 citations

Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies

Journal of the American Heart Association2016-06-1142 citations

Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes.

2010-07-279 citations